StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO – Free Report) in a research note released on Saturday morning. The firm issued a hold rating on the stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Ekso Bionics in a research note on Tuesday, July 30th.
View Our Latest Research Report on Ekso Bionics
Ekso Bionics Trading Down 15.0 %
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. During the same quarter in the previous year, the business posted ($0.24) earnings per share. On average, sell-side analysts predict that Ekso Bionics will post -0.42 EPS for the current year.
Hedge Funds Weigh In On Ekso Bionics
An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) by 322.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Read More
- Five stocks we like better than Ekso Bionics
- The Role Economic Reports Play in a Successful Investment Strategy
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Profitably Trade Stocks at 52-Week Highs
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What is the Hang Seng index?
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.